Transcription and signalling pathways involved in BCR–ABL‐mediated misregulation of 24p3 and 24p3R
暂无分享,去创建一个
[1] L. Hennighausen,et al. Distinctive Roles of STAT5a and STAT5b in Sexual Dimorphism of Hepatic P450 Gene Expression , 1999, The Journal of Biological Chemistry.
[2] D. Ayer,et al. Histone deacetylases: transcriptional repression with SINers and NuRDs. , 1999, Trends in cell biology.
[3] Christine Barett,et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. , 2006, Blood.
[4] B. Druker,et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy , 2002, Leukemia.
[5] B. Druker,et al. An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia , 2008, Leukemia.
[6] J. Hancock,et al. Ras Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase* , 1998, The Journal of Biological Chemistry.
[7] N. Liverton,et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. , 2002, Bioorganic & medicinal chemistry letters.
[8] H. Kantarjian,et al. Janus kinase 2: a critical target in chronic myelogenous leukemia. , 2006, Cancer research.
[9] J. G. Teodoro,et al. Induction of Apoptosis by a Secreted Lipocalin That is Transcriptionally Regulated by IL-3 Deprivation , 2001, Science.
[10] P. Warne,et al. Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras , 1997, Cell.
[11] H. Kantarjian,et al. Important Therapeutic Targets in Chronic Myelogenous Leukemia , 2007, Clinical Cancer Research.
[12] H. Kantarjian,et al. Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia. , 1989, Blood.
[13] F. Hobbs,et al. Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.
[14] M. Copland,et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. , 2008, Blood.
[15] B. Aggarwal,et al. Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia , 2004, Cancer Research.
[16] Alan Aderem,et al. Lipocalin 2 is required for BCR-ABL-induced tumorigenesis , 2008, Oncogene.
[17] H. Lin,et al. BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor , 2008, Oncogene.
[18] D. Levanon,et al. Structure and regulated expression of mammalian RUNX genes , 2004, Oncogene.
[19] Stephen Mackinnon,et al. Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia. , 2003, The New England journal of medicine.
[20] T. Skorski,et al. Oncogenic tyrosine kinases and the dna-damage response , 2002, Nature Reviews Cancer.
[21] Michael R. Green,et al. A Cell-Surface Receptor for Lipocalin 24p3 Selectively Mediates Apoptosis and Iron Uptake , 2005, Cell.
[22] P. A. Harris,et al. The discovery of potent cRaf1 kinase inhibitors. , 2000, Bioorganic & medicinal chemistry letters.
[23] E. Seto,et al. A Mechanism of Repression by Acute Myeloid Leukemia-1, the Target of Multiple Chromosomal Translocations in Acute Leukemia* , 2000, The Journal of Biological Chemistry.
[24] Michael R Green,et al. HIV-1 Tat Stimulates Transcription Complex Assembly through Recruitment of TBP in the Absence of TAFs , 2005, PLoS biology.
[25] M. Wigler,et al. Structure and activation of the human N-ras gene , 1983, Cell.
[26] T. Tauchi,et al. Imatinib Mesylate in Combination with Other Chemotherapeutic Agents for Chronic Myelogenous Leukemia , 2004, International journal of hematology.
[27] G. Daley,et al. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. , 2002, Blood.
[28] J. Belmont,et al. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia , 2005, Oncogene.
[29] F. E. Bertrand,et al. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis , 2004, Leukemia.
[30] J. Melo,et al. Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation. , 2004, Hematology/oncology clinics of North America.
[31] T. Meyer,et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.
[32] M. Wigler,et al. Multiple ras functions can contribute to mammalian cell transformation , 1995, Cell.
[33] Matthew B. Wilson,et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells , 2002, The EMBO journal.
[34] N. Donato,et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. , 2003, Blood.
[35] K Y Hui,et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.
[36] R. V. van Etten,et al. P210 and P190BCR/ABL Induce the Tyrosine Phosphorylation and DNA Binding Activity of Multiple Specific STAT Family Members* , 1996, The Journal of Biological Chemistry.
[37] N. Danial,et al. JAK-STAT signaling activated by Abl oncogenes , 2000, Oncogene.
[38] E. Nånberg,et al. Role of phosphoinositide 3OH‐kinase in autocrine transformation by PDGF‐BB * , 2001, Journal of cellular physiology.
[39] D. Frank,et al. Isolation of Unique STAT5 Targets by Chromatin Immunoprecipitation-based Gene Identification* , 2004, Journal of Biological Chemistry.
[40] Yusuke Nakamura,et al. Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray. , 2003, International journal of oncology.
[41] R. Ren,et al. Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.
[42] J. Belmont,et al. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model , 2001, Oncogene.
[43] A. Reiter,et al. Tyrosine kinase fusion genes in chronic myeloproliferative diseases , 2002, Leukemia.
[44] M. Barbacid. ras genes. , 1987, Annual review of biochemistry.